Session » Healthcare Disparities in Rheumatology Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1031

Access to Advanced Therapies in Axial Spondyloarthritis in Latin America, Data from the PANLAR-ESPALDA Registry

10:30AM-12:30PM: Abstract Number: 1029

An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network

10:30AM-12:30PM: Abstract Number: 1018

Analysis of Medication Usage and Monthly Costs in Hospitalized Patients with Rheumatic Diseases: A Retrospective Observational Study

10:30AM-12:30PM: Abstract Number: 1028

Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

10:30AM-12:30PM: Abstract Number: 1013

Burden of Emergency Department Visits and Their Outcomes Among Patients with Rheumatoid Arthritis: Insights from the Nationwide Emergency Department Sample (NEDS)

10:30AM-12:30PM: Abstract Number: 1012

Disparities in Time to Diagnosis for Radiographic Axial Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 1030

Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region

10:30AM-12:30PM: Abstract Number: 1027

Evaluation of Health Disparities in Outcomes of Patients with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 1023

Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors

10:30AM-12:30PM: Abstract Number: 1025

Gender Disparities in Disease Impact and Treatment Access for Spondyloarthropathies in Latin America: Insights from a Web Survey

10:30AM-12:30PM: Abstract Number: 1020

Health Inequalities Exist Between the United States and Europe for Patients with Axial Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 1026

Healthcare Utilization and Childhood Opportunity Index in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1032

Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities

10:30AM-12:30PM: Abstract Number: 1021

Improving Preoperative Osteoporosis Screening for Orthopedic Patients

10:30AM-12:30PM: Abstract Number: 1024

Increased Social Vulnerability Index Predicts Lower Likelihood of Remission in Rheumatoid Arthritis Patients

10:30AM-12:30PM: Abstract Number: 1017

Non-Adherence and Missed Appointments in Rheumatology: Pre and Post COVID-19 Pandemic Impact

10:30AM-12:30PM: Abstract Number: 1033

Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020

10:30AM-12:30PM: Abstract Number: 1015

Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1016

Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S

10:30AM-12:30PM: Abstract Number: 1014

Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes

10:30AM-12:30PM: Abstract Number: 1022

Social Determinants of Health in Osteoporosis Treatment Patterns Among Adults with Rheumatoid Arthritis and Major Osteoporotic Fracture in the All of Us Research Program: A Cross-Sectional Study

10:30AM-12:30PM: Abstract Number: 1019

The Impact of Race and Ethnicity and Historical Redlining on Psoriatic Disease Burden

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].